Initial research has focused on obesity, but Ozempic, Wegovy and Mounjaro may potentially be used for addiction, heart disease and Alzheimer’s
Experts expect Trump regulators to be less hawkish on challenging proposed acquisitions in the sector
And quality in the small cap rally
Company veteran Iskra Reic moves to Shanghai after Leon Wang placed under investigation by authorities
Report by industry group finds MHRA’s ‘capacity and predictability’ is biggest factor deterring investment
Experts forecast Trump administration could usher in new era of mergers and acquisitions among drugmakers
Abingworth wants to pursue royalty-based partnerships with major pharma groups
This is a time for treating people as individuals rather than as members of a tribe
Radical former Democrat wants to take on Big Pharma — but his team is already arguing
Author recommends breaking ‘siloed’ work practices to spur life sciences sector and improve care
State-backed insurance programmes would fund drugs for obese patients without separate health conditions
Trump nominee's vaccine scepticism worries industry
Trump nominee has caused concern in the industry due to his desire to reduce spending on medicines
Former investors and board members reduce holdings in the once much-hyped genetics-testing group
Chris Boshoff played role in drugmaker’s acquisition of Seagen, which has been criticised by investor
Robert F Kennedy Jr’s appointment is characteristic of Trump’s hostility to expertise
Danish company expects data to show that CagriSema cuts weight by 25 per cent in just over a year
Catalio Capital has survived choppy years in the sector and returned more than $300mn to its limited partners
GSK, Sanofi and Moderna shares all sink after Donald Trump chooses vaccine sceptic as top US health official
Vaccine sceptic and former Democrat is the latest controversial nomination for cabinet post
Sharp rise in cases over 30 years compounded by millions of people lacking access to medication, Lancet study finds
UK pharma group posts ‘statistically significant’ trial results for Blenrep when combined with another treatment
The UK pharmaceutical company needs to resolve a corruption crackdown affecting senior executives
Acquisition is latest example of western drugmakers turning to China to tap innovation
Deteriorating market conditions mean chief executive Bill Anderson will have to dig even deeper
